Abstract
The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 930-934 |
| Number of pages | 5 |
| Journal | Journal of Infectious Diseases |
| Volume | 154 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1986 |
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases
Fingerprint Dive into the research topics of 'Iontophoresis of vidarabine monophosphate for herpes orolabialis'. Together they form a unique fingerprint.
Cite this
Gangarosa, L. P., Hill, J. M., Thompson, B. L., Leggett, C., & Peter Kissing, J. (1986). Iontophoresis of vidarabine monophosphate for herpes orolabialis. Journal of Infectious Diseases, 154(6), 930-934. https://doi.org/10.1093/infdis/154.6.930